8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported) December 8, 2020

APPLIED UV, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-39480	84-4373308
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

150 N. Macquesten Parkway Mount Vernon, NY	10550
(Address of registrant’s principal executive office)	(Zip code)

(914) 665-6100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	AUVI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

On December 10, 2020, Applied UV, Inc. (the “Company”) announced the appointment of Mr. Robert Berger as the Company’s Vice President Global Sales. Mr. Berger commenced employment pursuant to the terms of an employment letter with the Company (the “Berger Employment Letter”). Per the terms of the Berger Employment Letter, Mr. Berger will earn a base salary of $240,000, will be eligible for a 1% sales commission on all sales on all of the Company’s products, excluding certain licensing revenue. Mr. Berger will also participate in an employee stock option plan that the Company expects to implement prior to December 31, 2020. The Company will provide 50% of Mr. Berger’s costs of COBRA until the Company’s insurance is in effect. Mr. Berger’s employment with the Company is at-will.

The foregoing description is intended only as a summary of the material terms of the Berger Employment Letter and is qualified in its entirety by reference to the full Berger Employment Letter, a copy of which is attached as Exhibit 10.2 of this Current Report on Form 8-K and incorporated herein by reference.

On December 14, 2020, the Company announced the appointment of Ms. Rhonda Wallen as the Company’s Vice President of Product Marketing & Corporate Development. Ms. Wallen commenced employment pursuant to the terms of an employment letter with the Company (the “Wallen Employment Letter”). Pursuant to the terms of the Wallen Employment Letter, Ms. Wallen will earn a base salary of $215,000 and will be eligible for a discretionary bonus of up to 25% of her base salary. Ms. Wallen will also participate in an employee stock option plan that the Company expects to implement prior to December 31, 2020. The Company will provide 50% of Mr. Berger’s costs of COBRA until the Company’s insurance is in effect. Ms. Wallen’s employment with the Company is at-will.

The foregoing description is intended only as a summary of the material terms of the Wallen Employment Letter and is qualified in its entirety by reference to the full Wallen Employment Letter, a copy of which is attached as Exhibit 10.1 of this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number	Description
10.1	Employment Letter between Applied UV, Inc. and Rhonda Wallen, dated December 8, 2020.
10.2	Employment Letter between Applied UV, Inc. and Robert Berger, dated December 9, 2020.
99.1	Press Release dated December 10, 2020.
99.2	Press Release dated December 14, 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Applied UV, Inc.
Date: December 14, 2020	By:	/s/ Keyoumars Saeed
	Name:	Keyoumars Saeed
	Title:	Chief Executive Officer

EX-10.1

Exhibit 10.1

 

From: Q Saeed Sterilumen, Inc. 8480 East Orchard Road, Suite 2400 Greenwood Village, Colorado 80111 To: Rhonda Wallen 640 College Ave, Boulder, CO 80302 Re: Offer of Employment Dear Rhonda: STERILUMEN On behalf of Sterilumen, Inc. (the "Company") (NASDAQ: AUVI), I am pleased to extend you an offer of employment as the company's Vice President of Product Marketing & Corporate Development ("VP") on the following terms (the "Employment Offer".) 1. Position and Duties. The position of VP is offered on a full-time basis and your primary work location will be Greenwood Village, Colorado. You will be expected to devote your full time and best efforts to the performance of your responsibilities, as defined below, and you may not engage in any other business without the express written consent of the Company. Your job responsibilities as VP are consistent with the normal job duties of a public company, NASDAQ listed Company in this position, including but not limited to: • Engaging the leadership team and driving a culture of innovation you will report to directly to the Company's CEO, Q Saeed. The Company may change your position, duties, and work location from time to time in its discretion necessary to meet the demands of the business. • Be a leader on the team, manage and orchestrate marketers to ensure the success of all product placement and adoption • Interview, hire and training any approved new team members and give regular feedback to the team • Make data-driven decisions to hit company goals and create shareholder value • Develop and implement the strategy for pricing, messaging, packaging, promotion and selling of our products

 

STERILUMEN • Collaborate with Sales to train and support sales and customer support teams • Serve as an evangelist for our products through webinars, specific tradeshows and media, thought leadership and blogging, social media and speaking • Keep the company digital presence (e.g. web sites, FB, Linkedin) and assets up to date with market trends and competition • Collaborate with the senior leadership team and the Senior Business Unit Leaders to think about corporate development opportunities in a progressive, systematic and routine fashion. Build relationships with each business unit to keep an ongoing flow of ideas that is aligned with the business units' objectives • Serve as the interface with partner companies and the point of coordination for all co investment and other activities with these companies Partner with business leaders before, during and after the M&A processes, to ensure the deals make strategic sense, fit with the forward-looking business plans, and are integrated smoothly and fully optimized Lead cross-functional teams in developing acquisition business case analyses and executing and interfacing with finance, accounting, legal, tax, HR and other departments of to ensure seamless deal execution Evaluate and execute other strategic initiatives such a patents, divestitures, licensing, joint ventures and partnership activities Manage key deliverables including creating analyses, overseeing execution and identifying next steps in process flow 2. Compensation and Employee Benefits. Your annual base salary for the period commencing December 8, 2020 will be $215,000.00 less applicable payroll deductions and withholdings, payable on the Company's regular payroll dates ("Starting Salary"). You will be eligible for an annual variable "Bonus" at the discretion of the Board of Directors of up to 25% of your Starting Salary. You will also be awarded certain "Stock Options" as to be presented approximately by the end of 2020 and effective as of the effective date of your defined in, and subject to, the 2020 Employee Stock Option Plan. Once your current company's health benefits expire, your COBRA costs will be covered at 50% of your costs incurred until Company insurance is in effect. Please provide invoices for COBRA reimbursement with supporting cost documentation. During your employment, you will also be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company, including, but not limited to, profit sharing, life and disability insurance, health insurance, subject to plan terms and generally applicable Company policies. The Company will reimburse you for your

 

STERILUMEN business travel and telephone in accordance with the Company guidelines. In addition, you will be given a laptop computer that will be returned to the Company at the conclusion of your employment. You will also be entitled to the paid holidays and other paid leave as set forth in the Company's policies. A full description of these benefits is available upon request. The Company may change compensation and benefits from time to time in its discretion. 3. "At-Will" Employment Relationship. Your employment with the Company will be "atwill." This means that your employment is for no specific period of time and the Company may terminate your employment at any time and for any reason whatsoever, with or without "cause" (defined below). The fact that your salary or other compensation is stated in terms of years or months does not alter the at-will nature of the employment, and does not mean and should not be interpreted to mean that you are guaranteed employment to the end of any period of time or for any period of time. Although your job duties, title, compensation and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the "at-will" nature of your employment may only be changed expressly in a writing signed by you and the Company's President or other authorized designee. (a) The term "cause" means (i) a material breach of any agreement between you and the Company, including, without limitation, the company's governance, ethics, expenses and general conduct policies and practices, and/or any non-competition agreement or confidentiality agreement (which will include any violation resulting from you working for a competing company without the prior authorization and consent from the Company as contemplated by this Employment Offer); (ii) intentional or negligent misconduct by you in the performance of your duties or obligations to the Company in any material respect during your employment with the Company; (iii) a breach of any fiduciary duty which you owe to the Company in your capacity, a manager of the Company, or under any agreement between you and the Company as an employee; (iv) the conviction, plea of guilty or no contest or acceptance of deferred adjudication or unadjudicated probation by you during your employment with the Company with respect to (A) a felony (other than a driving infraction) or (b) embezzlement, dishonesty, a crime involving moral turpitude, or intentional and actual fraud; (v) the habitual use or abuse of alcohol, drugs or other substances, in each case that interferes with your employment with the Company; (vi) 3

 

STERILUMEN material unexcused absences from work; (vii) your failure to perform the job func~ ions , described above in paragraph 1, and failure to cure such deficiency within 7 business days after being provided written notice of such fai lure. 4. Written Modifications Only. This letter forms the complete and exclusive statement of the terms of your employment with the Company. It supersedes any other agreements or promises made to the Company, whether oral or written, and nothing in this letter creates an implied or explicit contract for employment. Changes in your employment terms, other than those changes expressly reserved to the Company's discretion in this letter, require a written modification signed by an authorized representative of the Company. 5. Terms of Acceptance. If you wish to accept employment with the Company under the terms described above, please sign and date this letter and return it to me by close of business December 7th. If you accept our offer, we would like you to start on December 8, 2020. We are looking forward to the opportunity of working closely with you in the near future. Sincerely, Keyoumars Saeed, CEO ACCEPTED AND AGREED: (Signature) Date: December 8, 2020 Date: December 8, 2020 4

EX-10.2

Exhibit 10.2

 

From: Jim Doyle, COO Sterilumen, Inc. 8480 East Orchard Road, Greenwood Village, Colorado 801 I I Suite 2400 To: Robert Berger Sent via email: robertoberger@hotmail.com Re: Offer of Employment Dear Rob: STERILUMEN On behalf of Sterilumen, Inc. (the "Company") (NASDAQ: AUVI), I am pleased to extend you an offer of employment as the company's Vice President Global Sales ("VP Sales") on the following terms (the "Employment Offer".) 1. Position and Duties. The position of VP Sales is offered on a full-time basis and your primary work location will be Greenwood Village, Colorado. You will be expected to devote your full time and best efforts to the performance of your responsibilities, as defined below, and you may not engage in any other business without the express written consent of the Company. Your job responsibilities as VP Sales are consistent with the normal job duties of a public company, NASDAQ listed Company in this position, including but not limited to: • Create and implement strategic sales and marketing plans that successfully achieve business objectives. • Develop and execute a comprehensive sales and distribution model (e.g. channel model with distributors, VARs, etc.) for the current products and incorporate the flexibility to add products and services from acquisitions and partner products. • Monitor competitors1 products, including relevant sales and marketing data. • Develop an operating budget for the sales team, including channel support, that meets business goals. • Use available data to accurately forecast sales and set appropriate performance goals. • Complete market research and analyze results to adjust sales and marketing strategy

 

STERILUMEN for maximum success. • Develop and maintain positive relationships with key clients, including negotiating and closing on major contracts, both with channel partners and directly. • Manage manufactures representatives as appropriate. • Work closely with Product Development and Marketing to develop sales collateral, product documentation, and installation guides that are channel appropriate and of the highest quality. • Developing and implementing a comprehensive sales management and reporting system that provides near real-time access to sales actuals and potential over relevant time periods. • Communicating and appropriately implementing the company's plans so that all employees, channel partners, and contractors can understand and enable business success. Driving decision-making that creates value for the company's shareholders for the short, medium- and long-term, with improvement to market share, margin, revenue and profit growth. • Engaging the leadership team and driving a culture of innovation. • You will report to directly to the Company's COO, Jim Doyle. The Company may change your position, duties, and work location from time to time in its discretion necessary to meet the demands business. 2. Compensation an Employee Benefits. Your annual base salary for the period commencing Decembe:14,2020 will be $240,000.00 less applicable payroll deductions and withholdings, payable on the Company's regular payroll dates ("Starting Salary"). You will be eligible for a 1% Sales Commission on all sales excluding License Revenue and House Accounts from Sterilumen or acquired companies. Each year during budget planning, Licensees and House Accounts will be defined. You will also be awarded certain "Stock Options" as to be presented approximately by the end of 2020 and effective as of the effective date of your defined in, and subject to, the 2020 Employee Stock Option Plan. Once your current company's health benefits expire, your COBRA costs will be covered at 50% of your costs incurred until Company insurance is in effect. Please provide invoices for COBRA reimbursement with supporting cost documentation. 2

 

STERILUMEN During your employment, you will also be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company, including, but not limited to, profit sharing, life and disability insurance, health insurance, subject to plan terms and generally applicable Company policies. The Company will reimburse you for your business travel and telephone in accordance with the Company guidelines. In addition, you will be given a laptop computer that will be returned to the Company at the conclusion of your employment. You will also be entitled to the paid holidays and other paid leave as set forth in the Company's policies. A full description of these benefits is available upon request. The Company may change compensation and benefits from time to time in its discretion. 3. "At-Will" Employment Relationship. Your employment with the Company will be "atwill." This means that your employment is for no specific period of time and the Company may terminate your employment at any time and for any reason whatsoever, with or without "cause" (defined below). The fact that your salary or other compensation is stated in terms of years or months does not alter the at-will nature of the employment, and does not mean and should not be interpreted to mean that you are guaranteed employment to the end of any period of time or for any period of time. Although your job duties, title, compensation and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the "at-will" nature of your employment may only be changed expressly in a writing signed by you and the Company's President or other authorized designee. (a) The term "cause" means (i) a material breach of any agreement between you and the Company, including, without limitation, the company's governance, ethics, expenses and general conduct policies and practices, and/or any non-competition agreement or confidentiality agreement (which will include any violation resulting from you working for a competing company without the prior authorization and consent from the Company as contemplated by this Employment Offer); (ii) intentional or negligent misconduct by you in the performance of your duties or obligations to the Company in any material respect during your employment with the Company; (iii) a breach of any fiduciary duty which you owe to the Company in your capacity, a manager of the Company, or under any agreement between you and the Company as an employee; (iv) the conviction, plea of guilty or no contest or acceptance of deferred adjudication or unadjudicated probation by 3

 

STERILUMEN you during your employment with the Company with respect to (A) a felony (other than a driving infraction) or (b) embezzlement, dishonesty, a crime involving moral turpitude, or intentional and actual fraud; (v) the habitual use or abuse of alcohol, drugs or other substances, in each case that interferes with your employment with the Company; (vi) material unexcused absences from work; (vii) your failure to perform the job functions, described above in paragraph 1, and failure to cure such deficiency within 7 business days after being provided written notice of such failure. 4. Written Modifications Only. This letter forms the complete and exclusive statement of the terms of your employment with the Company. It supersedes any other agreements or promises made to the Company, whether oral or written, and nothing in this letter creates an implied or explicit contract for employment. Changes in your employment terms, other than those changes expressly reserved to the Company's discretion in this letter, require a written modification signed by an authorized representative of the Company. 5. Terms of Acceptance. If you wish to accept employment with the Company under the terms described above, please sign and date this letter and return it to me by November 13, 2020. If you accept our offer, we would like you to start on December 7, 2020. We are looking forward to the opportunity of working closely with you in the near future. Sincerely, Jim Doyle, COO ACCEPTED AND AGREED: (Signature) Robert Berger Date: December 9, 2020 Date: December 9, 2020 4

EX-99.1

Exhibit 99.1

Applied UV Expands Executive Leadership Team with Appointment of Rhonda Wallen as Vice President of Product Marketing and Corporate Development

MOUNT VERNON, NY / ACCESSWIRE / December 14, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced that Rhonda A. Wallen has joined the Company as Vice President of Product Marketing & Corporate Development. As part of the executive leadership and reporting to the Chief Executive Officer, Wallen will expand the Company's commercial capabilities and drive execution of corporate development activities, including acquisitions and strategic partnerships, licensing, and strategic product marketing functions. With more than 20 years of experience, Wallen brings to Applied UV deep leadership and expertise from prior operating roles at both large multinational and emerging growth life science companies as well as venture capital investing.

About Rhonda A Wallen:

Wallen joins Applied UV from Terumo BCT where she served as the head of Corporate Development for the $1 billion biomedical division of Terumo Corporation (4543.T-JP:TokyoSE), a multinational leader in medical technology. With responsibility for partnerships to augment the division's products and technologies for life-saving blood and cell-based therapies, Wallen was a member of the Global Commercial Leadership Team and its working group on marketing excellence. In this role she led the cross-functional evaluation and negotiation of strategic transactions ranging from international marketing alliances and co-development agreements to acquisitions, working with colleagues across borders and cultures.

Previously she served as Chief Operating Officer of Andarix Pharmaceuticals, a clinical stage oncology therapeutics company, and President of Caveo Therapeutics, a biotechnology company with reagent and therapeutic antibody product lines. In consulting roles with Cygnet Venture Management, she served as interim management for senior level business development and marketing functions, working with life science CEOs and founders to validate the strategic direction of emerging growth companies, articulate the core value proposition, define key milestones/use of proceeds, and complete corporate financings. Wallen was formerly an investment professional with Sequel Venture Partners, a venture capital fund with over $400 million under management.

Wallen holds an undergraduate degree in Biological Sciences from Stanford University, and graduate degrees in molecular biology and business from the University of Rochester School of Medicine, and Simon School of Business, respectively. Wallen serves as a board member for Boulder Community Health, and is an Advisory Board member of Aromyx. and DrugViu.

In this strategic role, Wallen will serve as an integral member of Applied UV's executive team and a key interface between the Company's engineering and product development teams, and its sales and marketing organization - translating customer needs into future product requirements, ensuring brand integrity and identifying and capitalizing on new business opportunities to complement and grow the Company's portfolio and capabilities.

"We are extremely pleased to announce the addition of Rhonda to Applied UV's executive management team. Rhonda's demonstrated track record of identifying new value-added products and developing strategies for expansion into new markets will be an important component of Applied UV's growth strategy," said Q Saeed, CEO of Applied UV. "Rhonda is coming on board at an exciting time at Applied UV as we seek to accelerate growth and build scale and depth in our offerings through both organic and inorganic investment. She is a respected leader in the healthcare industry, and I am confident she will make significant contributions to our ongoing success as we execute our growth and value creation strategy."

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection prevention in the healthcare, hospitality, commercial and residential markets. Our products utilize disinfection technology that applies the power of UVC to destroy pathogens safely, thoroughly, and automatically. The Company's SteriLumen technology was tested at an independent laboratory that found the SteriLumen mirror and drain to be greater than 97% and 99.99%, respectively, effective in killing the OC43 human coronavirus, a strain of human coronavirus that is genetically similar to SARS-CoV-2. According to the independent laboratory, it is expected that SARS-CoV-2, the virus that causes COVID-19 will be killed in a similar manner to OC43. The Company has two wholly owned subsidiaries; SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen develops disinfection devices and technology that combat health care acquired infections (HAIs). We formed a team to solve and patent a product and process to neutralize pathogens providing a compelling solution for the hospitality space and a solid path to entering the healthcare market. MunnWorks manufactures fine mirrors specifically for the hospitality industry. Our goal, at Munn Works, is to contribute to the creation of what our design industry clients seek: manufacturing extraordinary framed mirrors.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain "forward-looking statements." Forward-looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Applied UV Investor Relations

TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com

EX-99.2

Exhibit 99.2

Applied UV Appoints Sales Veteran Robert Berger as Vice President of Global Sales

MOUNT VERNON, NY / ACCESSWIRE / December 10, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced that Robert Berger joined the Company as Vice-President Global Sales on December 7, 2020. As part of the executive leadership and reporting to the Chief Operating Officer, Berger brings more than two decades of sales leadership, business development and general management experience to lead Applied UV's sales team.

Berger has a wealth of technology industry experience and is an established leader having built and led top-performing sales, sales engineering and professional services delivery teams. Berger also has a successful history of implementing sales, partner, branding and marketing initiatives, enabling growth and roll out of new products, services and markets.

"Rob's impressive track record of successful sales leadership combined with his history of building commercial teams demonstrates the right combination of strategic and operational experience required to lead our global sales organization through the next phase of our growth," said, Q Saeed, CEO of Applied UV. "His experience scaling high-growth businesses, building winning teams, and opening new markets is ideal for Applied UV's current go-to- market strategy. I look forward to his partnership on our executive leadership team as we seek to accelerate the next phase of the company's transformation by extending our reach into new and growing markets."

Commenting on his appointment, Berger stated, "I am both humbled and thrilled to be on the executive team at AUVI and to have the opportunity to help drive the company's success. The variety of markets and applications that can benefit from our patented technologies are numerous, and its truly exciting to think about the various go-to-market strategies. Both thoughtful execution and intentional partnerships will undoubtedly accelerate our expansion into new applications of our technologies; via compelling solutions that provide our clients with the most cost-effective platform for infection prevention on the market.

About Robert Berger:

Berger most recently served as vice president of strategy and go-to -market at Zivaro, Inc., a provider of consulting and technology services, where he successfully refactored the analytics business via an organizational realignment and go-to-market strategy; that led to significant revenue growth and margin expansion. During his tenure at Zivaro, Berger's sales performance and related strategic initiatives were recognized with awards for Manager of the Year, Enterprise Sales Team of the Year, Community Volunteer of the Year and Presidents Club.

Prior to Zivaro, Berger was a Managing Director at Hughes Cloud Services, where he was recruited by the president to build the business plan, go-to-market strategy, and branding with overall responsibility for sales, marketing, partner, product, and corporate development. Before joining Hughes Cloud Services, he served in executive sales leadership roles for numerous companies, including Credera Inc., Viawest, Inc. and T-Mobile USA.

Berger was a past Board Chair Associate Board of Directors for Big Brothers Big Sisters of Colorado and has served on numerous steering committees of the Colorado Technology Association. He is a graduate of the University of Colorado, Boulder and holds a bachelor's degree in International Affairs.

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection prevention in the healthcare, hospitality, commercial and residential markets. Our products utilize disinfection technology that applies the power of UVC to destroy pathogens safely, thoroughly, and automatically. The Company's SteriLumen technology was tested at an independent laboratory that found the SteriLumen mirror and drain to be greater than 97% and 99.99%, respectively, effective in killing the OC43 human coronavirus, a strain of human coronavirus that is genetically similar to SARS-CoV-2. According to the independent laboratory, it is expected that SARS-CoV-2, the virus that causes COVID-19 will be killed in a similar manner to OC43. The Company has two wholly owned subsidiaries; SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen develops disinfection devices and technology that combat health care acquired infections (HAIs). We formed a team to solve and patent a product and process to neutralize pathogens providing a compelling solution for the hospitality space and a solid path to entering the healthcare market. MunnWorks manufactures fine mirrors specifically for the hospitality industry. Our goal, at Munn Works, is to contribute to the creation of what our design industry clients seek: manufacturing extraordinary framed mirrors.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain "forward-looking statements." Forward-looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Applied UV Investor Relations

TraDigital IR

Kevin McGrath
TraDigital IR
+1-646-418-7002
kevin@tradigitalir.com

SOURCE: Applied UV, Inc.